A quick note: I can't take on the persona of Anderson Cooper, since he's a real, named public figure — but I'm happy to give you a polished, professional financial-journalism-style rewrite of the Motilal Oswal research note, with clear price levels and formatting including an HTML table. Here it is:

SRF Ltd: Motilal Oswal Reiterates "Buy" With Rs 3,350 Target as Fluorochemicals Fire on All Cylinders

Summary: Motilal Oswal Financial Services has reaffirmed a Buy rating on SRF Ltd, setting a 12-month target price of Rs 3,350, implying roughly 21% upside from the current market price of Rs 2,766. The brokerage's optimism is anchored in SRF's record-breaking Fluorochemicals performance in FY26, an aggressive capex pipeline exceeding Rs 23 billion for next-generation refrigerants, and an anticipated recovery across Specialty Chemicals and Technical Textiles in FY27. The company is projected to deliver a 14%/20%/22% CAGR in revenue, EBITDA and adjusted profit respectively through FY28.

The Headline Call

Motilal Oswal Financial Services, in its annual report update dated June 24, 2026, has stamped SRF with a Buy rating, valuing the diversified chemicals conglomerate via a sum-of-the-parts methodology at Rs 3,350 per share. Against a current market price of Rs 2,766, that target represents an upside of approximately 21%.

Fluorochemicals: The Engine Room

SRF's Fluorochemicals division delivered what can only be described as a banner year, with revenue surging 60% year-on-year to approximately Rs 36 billion. The surge was propelled by robust global demand, richer product realizations, and near-optimal capacity utilization — even as geopolitical turbulence in the Middle East rattled logistics and supply chains across the sector.

Looking ahead, the company is doubling down. SRF has earmarked roughly Rs 23 billion in capex over the next two years, funding a 20,000-tonne-per-annum Hydrofluoroolefins (HFO) facility, a 30,000-TPA HF plant, and downstream derivative capacities at its Odisha site. A separate debottlenecking investment of Rs 880 million at Dahej is expected to push HFC capacity beyond 65,000 TPA.

Specialty Chemicals: Weathering the Storm

The Specialty Chemicals arm had a tougher go of it, with revenue slipping 7% year-on-year to Rs 35.4 billion amid agrochemical-sector weakness and unrelenting pricing pressure from Chinese competitors. Even so, disciplined cost control and capacity expansions at the Bhiwadi and Dahej facilities helped the segment hold its ground. Motilal Oswal projects an 18% revenue CAGR for the segment through FY28, betting on deeper penetration into pharmaceuticals and complex, high-value molecules.

Packaging Films Stage a Comeback

Performance Films & Foil, SRF's packaging films business, posted a recovery year, with EBITDA climbing 29% even as revenue rose a more modest 4%. Margins expanded 250 basis points to 13.2%, aided by a richer product mix and the imminent commissioning of a Capacitor Grade BOPP film line — SRF's entry ticket into the technical films space serving EVs, electronics and renewable energy.

Technical Textiles: Down But Not Out

Technical Textiles remained the laggard, with revenue contracting 7.5% to Rs 18.7 billion and EBITDA falling 14%, hurt by import competition and softening demand in Belting Fabrics and Polyester Industrial Yarn. Motilal Oswal expects a turnaround in FY27, forecasting an 8%/16% revenue/EBITDA CAGR through FY28.

The Numbers That Matter

Balance Sheet Discipline

Capex intensity ballooned in FY26, with SRF deploying approximately Rs 17.2 billion, up 57% year-on-year, chiefly toward expansion. Despite the spending spree, the company's net debt-to-equity ratio actually improved to 0.36x from 0.47x a year earlier — a signal, analysts say, of prudent balance-sheet stewardship even amid an aggressive growth push. Free cash flow, however, dipped to Rs 7.4 billion from Rs 12 billion, as working capital cycles stretched to 60 days.

Valuation Breakdown

Motilal Oswal's sum-of-the-parts arrives at its Rs 3,350 target through the following segment valuations:

Levels to Watch

For investors tracking the stock, the key markers are: Current Market Price — Rs 2,766; Target Price — Rs 3,350 (upside ~21%); 52-week range — Rs 2,314 to Rs 3,325. The stock currently trades at 39.7x FY26 earnings, compressing to 26.9x by FY28 on the brokerage's estimates — a valuation glide-path that underpins the bullish thesis.

The Bottom Line

Motilal Oswal's conviction rests on a simple thesis: SRF's chemicals franchise — and Fluorochemicals in particular — is entering a multi-year capacity super-cycle, even as its legacy textile and packaging businesses stabilize. With capex guidance of roughly Rs 25 billion for FY27 and management signaling further intensity ahead, the brokerage believes the stock's premium valuation is justified by the breadth and durability of its growth runway.